sorafenib has been researched along with tigecycline in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (tigecycline) | Trials (tigecycline) | Recent Studies (post-2010) (tigecycline) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,999 | 68 | 1,285 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ardelt, MA; Arnold, GJ; Fröhlich, T; Gerbes, AL; Huber-Cantonati, P; Kiemer, AK; Koeberle, A; Koenig, LM; Meßner, M; Müller, M; Ortler, C; Pachmayr, J; Pein, H; Rothenfußer, S; Schmitt, S; Vollmar, AM; Zischka, H; Zobel, L | 1 |
1 review(s) available for sorafenib and tigecycline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sorafenib and tigecycline
| Article | Year |
|---|---|
Metabolic implication of tigecycline as an efficacious second-line treatment for sorafenib-resistant hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Mice, SCID; Mitochondria; Neoplasm Recurrence, Local; Protein Synthesis Inhibitors; Sorafenib; Tigecycline; Xenograft Model Antitumor Assays | 2020 |